We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against other worst ARK stocks to buy according to short sellers.
Cathie Wood of ARK Investment is one of Wall Street’s most well-known hedge fund bosses. In a hedge fund industry dominated by players that focus on quantitative trading, value stocks, and balanced portfolios, Wood stands out from the pack by focusing on disruptive innovation and firms that she and her firm believe will change the world.
This relentless focus on change means that if the economy is facing turbulence, then markets are not kind to Wood. To understand how: consider the cumulative value of her firm’s holdings as indicated by its 13F SEC filings. Starting from Q3 2020, analyzing the value for each subsequent year’s third quarter reveals how Ark Invest’s fortune fluctuates with economic winds. The hedge fund’s holdings were valued at $16.8 billion, $41.6 billion, $14.3 billion, and $13 billion during Q3 2020, Q3 2021, Q3 2022, and Q3 2023, respectively.
This shows that the value of Ark Invest’s holdings jumped by 148% between the third quarters of 2020 and 2021. Looking back to see why, market conditions back then were marked by easy liquidity, a surge in retail investing, and Wall Street’s bullishness for technology stocks. Technology and growth stocks are precisely the kinds that Wood invests in, and in the time period being analyzed, the shares of Elon Musk’s car company alone soared by 87%. Wood is one of the firm’s largest investors, and her patience has yielded results. Insider Monkey’s data shows that Ark Invest first bought the shares at an average price of $13.14 during Q4 2016. While it has grown its holdings from the 274,725 shares held back then to 4.6 million shares as of Q3 2024, even if Wood hadn’t bought additional shares, her original holdings would currently be worth $62.7 million right now for a remarkable 1,508% gain!
Yet, while Musk’s company is Wood’s greatest hit, there have been misses as well since the idea of investing in disruptive innovation carries the unavoidable pitfall of targeting some firms that fail to deliver on lofty ideas. We analyzed the share price performance of some of her longest-held stocks as part of our coverage of 10 Best Stocks to Buy and Hold For 5 Years According to Cathie Wood. At the time the list was published, its three worst-performing stocks were down by 81.85%, 95.11%, and 99% since 2020 end. Extrapolating their performance to December 2024, the first two stocks, which rank 2nd and 4th have lost 75% and 94.5%.
At the heart of Ark Invest’s trading strategy is the fund’s flagship ARK Innovation ETF fund. Over the past five years, this fund has gained a modest 23% which is substantially lower than the flagship S&P index’s 93.5%. Zooming into its 2024 performance, this fund has gained 20.5% while the index is up by 28.3%.
Wood’s ETF’s performance can also be divided into pre and post-election gains. Before the election, it was down 7.6% year-to-date after having bled 13% during H1 2024. As H1 ended, Wood acknowledged the troubling time her firm was facing in an investor letter. She admitted “fully that the macro environment and some stock picks have challenged our recent performance” but went on to add that her firm’s “conviction in and commitment to investing in disruptive innovation have not wavered.” According to Wood, Ark had to remain persistent back then since exiting our strategies now would crystallize losses that lower interest rates and reversions to the mean should transform into meaningful profits during the next few years.”
The mean reversion she is referring to is the differential in the performance between the Russel Value and Growth stock indexes in the infamous dot-com bubble. Wood pointed out that “At its worst in 2000, the Russell Value Index underperformed the Russell Growth Index by more ~3,500 basis points on a year-over-year basis but, within roughly one year, the relative performance flipped and reached a positive ~4,800 basis points, more than an 80-percentage point swing, as shown below.” She believes that Ark’s strategy to diversify away from the Magnificent 6 (Magnificent 7 ex Tesla) through “increased exposure to multiomics stocks that have been hit hardest by “higher for longer” interest rates” led to disappointing performance.
The potential upside from this diversification was evident in 2023 as the flagship fund “appreciated 68% as the bull market started to broaden out based on just the “whiff” of lower interest rates, despite its diversification away from the Magnificent Six and toward what we believe are more disruptive names,” according to Wood. To wit, while the flagship fund was down 7.6% YTD before the election after the ballots were cast and counted, it has gained 26% to bring its YTD performance to 20.46%. The benchmark S&P index, on the other hand, is up by 28.3%.
Our Methodology
For our list of the worst Ark stocks to buy according to short sellers, we ranked the 110 largest holdings in Ark Invest’s Q3 2024 SEC filings by the percentage of shares outstanding that were sold short and selected the stocks with the highest percentage.
For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).
A pharmacist in a hospital pharmacy stands next to a row of various drug containers.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Short Interest as % of Shares Outstanding: 22.53%
Number of Hedge Fund Investors In Q3 2024: 16
Ark Invest’s Q3 2024 Stake: $215.9 million
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is a pre-revenue stage biotechnology company that is developing treatments for a wide variety of illnesses. These include cancer, spine ailments, and brain diseases. While most pre-revenue biotechnology firms depend on a handful of drugs in their portfolio, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands out from the back by having more than ten drugs in trials. One drug that is key to its hypothesis is its brain illness treatment REC-994, which met key objectives during its Phase 2 trial. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) also benefits from a strong technological aspect through which it has collaborated with Google Cloud and NVIDIA for drug discovery. NVIDIA has invested $50 million in the firm for AI-driven drug discovery, and as it waits to commercialize any drugs, Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) earns money through partnerships with firms such as Exscientia.
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) management shared key details about its Exscientia partnership during the Q2 2024 earnings call. Here is what they said:
“And I think this deal, in many ways, will make Recursion perhaps a partner of choice for others in the industry. Finally, our platform. Our platforms at Recursion really focused on exploration of biology, hit discovery, target discovery. We’ve been building that for over a decade, and our colleagues at Exscientia have really been building for about the same amount of time this incredible precision chemistry platform. The ability to go from a hit to a development candidate with active learning and automated synthesis, is really, really exciting to us and putting these two platforms together, we think, is going to put us on the cutting edge. And finally, when we combine these businesses, we believe that we will have not only the team, the tools and the technology to go to the distance, but we’ll also have the resources to do that.
At the end of Q2, the companies combined have roughly $850 million, which we believe, with the right kind of operational synergies, puts us on a runway into 2027.”
Overall, RXRX ranks 2nd on our list of worst ARK stocks to buy according to short sellers. While we acknowledge the potential of RXRX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RXRX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.
